Looking for Lilly’s LY4086940? Its two registered trials, NCT06945419 and NCT07890376, are listed below. For what they test and what has not been disclosed, see the LY4086940 profile or our LY4086940 write-up.
4 registered trials, newest registry update first. Showing only trials linked to VK2735.
| Trial | Compound | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|---|
| Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) NCT07868835 | VK2735 | Phase 3 | Recruiting | Viking Therapeutics, Inc. | 560 | Jul 2028 | Nov 16, 2026 |
| Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) NCT07868939 | VK2735 | Phase 3 | Recruiting | Viking Therapeutics, Inc. | 560 | Oct 2028 | Nov 16, 2026 |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) NCT07104383 | VK2735 | Phase 3 | Active not recruiting | Viking Therapeutics, Inc. | 1,100 | Jul 1, 2027 | Apr 7, 2026 |
| VK2735 for Weight Management Phase 3 NCT07104500 | VK2735 | Phase 3 | Active not recruiting | Viking Therapeutics, Inc. | 4,500 | Jul 1, 2027 | Nov 24, 2025 |
Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.